Retatrutide is an investigational triple-hormone receptor agonist currently in Phase 3 clinical trials for the treatment of obesity and type 2 diabetes. While it has demonstrated significant weight loss outcomes in early studies, it is not currently FDA-approved for any medical use. It functions by targeting three distinct receptors—GLP-1, GIP, and glucagon—to regulate appetite and metabolic rate.
What is Retatrutide and How Does it Work?
Retatrutide is a synthetic peptide developed by Eli Lilly and Company. Unlike current weight management medications like semaglutide (Wegovy), which target the GLP-1 receptor alone, or tirzepatide (Zepbound), which targets GLP-1 and GIP, retatrutide acts as a "triple agonist."
According to results published in the New England Journal of Medicine, the drug mimics three hormones naturally produced in the gut and pancreas. By activating these three receptors simultaneously, the medication may theoretically provide a more potent effect on hunger signals and energy expenditure. The drug is administered via a weekly subcutaneous injection, similar to other medications in the incretin class.
Clinical Trial Results and Weight Loss Data
In a Phase 2 clinical trial involving 338 adults with obesity, participants receiving the highest dose of retatrutide (12 mg) experienced an average weight reduction of 24.2% after 48 weeks. For comparison, participants in the placebo group saw an average weight loss of 2.1% during the same period.
These findings, reported by the trial investigators in 2023, suggest that the triple-agonist approach may offer greater efficacy than existing dual-agonist therapies. However, researchers emphasize that these results remain preliminary until the ongoing Phase 3 trials—which include a much larger and more diverse patient population—are completed and peer-reviewed.
Common Side Effects and Safety Profile
The safety profile of retatrutide observed in early trials is consistent with other medications that target GLP-1 and GIP receptors. According to the study data, the most frequently reported adverse events were gastrointestinal in nature.
- Nausea
- Diarrhea
- Vomiting
- Constipation
These side effects were generally dose-dependent and most common during the initial period of dose escalation. As with other incretin mimetics, researchers are monitoring for potential risks, including gallbladder-related issues and the impact on lean muscle mass. Because the drug is still in the experimental phase, its long-term safety profile remains unknown.
Current Status and Regulatory Timeline
Retatrutide is not available for purchase or prescription. It is currently being evaluated in late-stage Phase 3 clinical trials, which are the final hurdle before a manufacturer can submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
The FDA approval process requires extensive evidence of both safety and efficacy. If the Phase 3 trials confirm the findings from the earlier study, Eli Lilly may seek regulatory approval for the drug as a treatment for chronic weight management and type 2 diabetes. Patients interested in accessing the medication must participate in a registered clinical trial, as the drug is not authorized for off-label use or commercial sale.
Frequently Asked Questions
Is retatrutide the same as Zepbound?
No. While both are developed by Eli Lilly, Zepbound (tirzepatide) is an FDA-approved dual-agonist targeting GLP-1 and GIP receptors. Retatrutide is an investigational triple-agonist that also targets the glucagon receptor.
When will retatrutide be available?
There is no set release date. The drug remains in clinical development, and approval depends on the outcomes of ongoing Phase 3 trials and subsequent FDA review.
How is retatrutide taken?
In clinical trials, the medication is administered through a weekly injection under the skin, similar to other injectable weight management therapies currently on the market.